Search
Muraglitazar
go.drugbank.com/drugs/DB06510Investigationalin LDL-C levels. … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingAMGN-0007
go.drugbank.com/drugs/DB06511ExperimentalRecombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.
Tesaglitazar
go.drugbank.com/drugs/DB06536InvestigationalTesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development. … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Robalzotan
go.drugbank.com/drugs/DB06538ExperimentalSynonyms: (R)-3-(Dicyclobutylamino)-8-fluoro-5-chromancarboxamideCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingR107474
go.drugbank.com/drugs/DB06553ExperimentalSynonyms: 3-(2-(3,4-Dihydrobenzofuro(3,2-c)pyridin-2(1H)-yl)ethyl)-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one, 3-[2-(3,4-dihydro-1H-[1]benzofuro[3,2-c]pyridin-2-yl)ethyl]-2-methylpyrido[1,2-a]pyrimidin-4-oneCategories: Heterocyclic Compounds, 1-RingTezosentan
go.drugbank.com/drugs/DB06558InvestigationalTezosentan is an intravenous endothelin receptor A/B antagonist.
Categories: Heterocyclic Compounds, 1-RingAM336
go.drugbank.com/drugs/DB06563ExperimentalIt was investigated as a potential treatment for various pain conditions.
Categories: Calcium Channels, N-Type